Immunovant (IMVT) has been drawing attention after recent share price moves, with the stock up about 24% over the past month and about 21% over the past 3 months, prompting closer scrutiny from biotech investors.

At the current share price of US$33.50, Immunovant’s recent 30 day share price return of 24.12% and year to date share price return of 29.29% sit alongside a 1 year total shareholder return of 124.98%. This indicates strong momentum over both shorter and longer horizons.

If Immunovant’s move has you looking beyond a single biotech stock, this could be a useful moment to scan the broader opportunity set with the Simply Wall St screener for 35 healthcare AI stocks

With Immunovant still loss making and yet valued at about US$6.86b, the recent surge raises a key question for you: is there still mispricing here, or is the market already baking in the company’s future potential?

Most Popular Narrative: 18.5% Undervalued

Immunovant’s most followed narrative pegs fair value at about $41.13 per share versus the last close of $33.50. This centers the discussion on how future autoimmune revenues might support that gap.

The fully enrolled D2T RA study for IMVT-1402, upsized to 170 patients, reflects strong physician and patient engagement that could support broader adoption in difficult to treat autoimmune populations over time, which would be most visible in revenue growth if late stage data are supportive.

Curious what kind of future revenue build this story leans on, and how profit margins and rich valuation multiples are stitched together to back that fair value.

Result: Fair Value of $41.13 (UNDERVALUED)

However, this story still leans heavily on IMVT-1402 trial success and assumes future margins and P/E well above current US biotech sector levels.

Next Steps

If this upbeat narrative around Immunovant feels compelling, treat it as a prompt to check the numbers and cross check the concerns investors are flagging through the 5 important warning signs.

Looking for more investment ideas?

If Immunovant is on your radar, do not stop here; broaden your watchlist now so you are not scrambling when the next opportunity appears.

• Spot potential breakouts early by scanning 23 elite penny stocks with strong financials, which pair smaller share prices with solid underlying metrics.
• Target value focused opportunities by reviewing 46 high quality undervalued stocks, which combine quality fundamentals with price tags that still look reasonable.
• Prioritise strength and staying power by checking solid balance sheet and fundamentals stocks screener (46 results), which highlight companies with healthier financial foundations.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.